Commentary

Video

Carving Out a Career in Medical Education

Author(s):

Sam Brondfield, MD, MAEd

Sam Brondfield, MD, MA, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses careers in medical education.

Sam Brondfield, MD, MA, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses careers in medical education.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP
Related Content
Jeff Patton, MD
September 24th 2024

Medicare Drug Price Negotiations Will Have Domino Effect for Community Oncology Practices

Samuel A. Kareff, MD, MPH, outgoing chief fellow, hematology and medical oncology, University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital
October 21st 2024

Phase 1 Trials Provide Oncology Fellows With Valuable Clinical Research Experience: With Samuel A. Kareff, MD, MPH

Debra Patt, MD, PhD, MBA, FASCO, of Texas Oncology
September 5th 2024

Medicare Drug Price Negotiation Program Will Result in Financial Burdens for Community Oncology Practices

Kevin Raskin, MD
June 5th 2023

Raskin Reflects on the Career-Long Role of Fellowship and Education in Orthopaedic Oncology

Debra Patt, MD, PhD, MBA, FASCO
September 3rd 2024

Vice President of COA Unpacks Effects of the Medicare Drug Price Negotiation Program in the Community

Marjorie Green, MD
August 29th 2024

Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC